TEXAS BIOMEDICAL RESEARCH INSTITUTE: Single Audit Reports and Findings

TEXAS BIOMEDICAL RESEARCH INSTITUTE filed 10 single audits between 2016 and 2025; the most recently observed auditor is ERNST & YOUNG LLP (2025), and the 2025 report lists 1 finding. Data as of 2026-11-06.

Data as of Nov 6, 2026 · Source: Federal Audit Clearinghouse (public data)

Single audits by year

One row per audit year as the Federal Audit Clearinghouse accepted it. The auditor named is the one observed on that filing; TEXAS BIOMEDICAL RESEARCH INSTITUTE is recorded in SAN ANTONIO, Texas under EIN 741109630, and the Clearinghouse records it as a nonprofit. Each report opens on the Clearinghouse itself; how to search the Federal Audit Clearinghouse explains the rest of the reporting package.

Single audits filed by TEXAS BIOMEDICAL RESEARCH INSTITUTE
Audit yearFiscal year endFederal expendedThreshold appliedAuditor observedFindingsMW / SDFAC report
20252025-12-31$54,077,608$1,000,000ERNST & YOUNG LLP1—2025-12-GSAFAC-0000420793
20242024-12-31$45,600,408$750,000ERNST & YOUNG LLP2SD2024-12-GSAFAC-0000381780
20232023-12-31$48,586,140$750,000ERNST & YOUNG LLP4SD2023-12-GSAFAC-0000054769
20222022-12-31$38,129,999$750,000ERNST & YOUNG LLP2SD2022-12-CENSUS-0000101110
20212021-12-31$34,454,598$750,000ERNST & YOUNG LLP0—2021-12-CENSUS-0000101110
20202020-12-31$34,077,564$750,000ERNST & YOUNG LLP0—2020-12-CENSUS-0000101110
20192019-12-31$34,194,652$750,000ERNST & YOUNG LLP0—2019-12-CENSUS-0000101110
20182018-12-31$32,279,060$750,000ERNST & YOUNG LLP1SD2018-12-CENSUS-0000101110
20172017-12-31$32,352,780$750,000ERNST & YOUNG LLP1SD2017-12-CENSUS-0000101110
20162016-12-31$30,563,607$750,000ERNST & YOUNG LLP1SD2016-12-CENSUS-0000101110

When is the next single audit due?

If TEXAS BIOMEDICAL RESEARCH INSTITUTE is again required to have a single audit for the fiscal year ending Dec 31, 2026, the reporting package is due to the Federal Audit Clearinghouse by Sep 30, 2027 at the latest.

Whether an audit is required depends on federal awards expended in that year (the single audit threshold). The rule, 2 CFR 200.512(a): the reporting package is due within 30 calendar days after the auditee receives the auditor's report or nine months after the end of the audit period, whichever is earlier; the date above is the nine-month date, moved to Monday when it falls on a weekend. Last verified: 2026-11-15.

Which federal programs did this organization report?

From the most recent accepted report, as listed on its schedule of expenditures of federal awards (SEFA). "Major" is the designation the auditor made under 2 CFR 200.518, not ours.

Federal programs on the most recent report
ALNProgramExpendedMajor
93.855ALLERGY AND INFECTIOUS DISEASES RESEARCH$14,500,757Yes
93.351RESEARCH INFRASTRUCTURE PROGRAMS$10,424,772Yes
93.RDCorrelate of Protection (CoP) Studies to Support Development of the cAd3-EBO-S (Sudan virus) Candidate Vaccine$4,962,039Yes
12.351SCIENTIFIC RESEARCH - COMBATING WEAPONS OF MASS DESTRUCTION$2,459,620Yes
93.RDBARDA RTOR BIO-AMT-2301: IDIQ Contact Management Support Activities$2,298,211Yes
93.352CONSTRUCTION SUPPORT$2,223,741Yes
11.307ECONOMIC ADJUSTMENT ASSISTANCE$2,033,086Yes
93.242MENTAL HEALTH RESEARCH GRANTS$1,245,085Yes
93.279DRUG USE AND ADDICTION RESEARCH PROGRAMS$1,006,570Yes
93.855ALLERGY AND INFECTIOUS DISEASES RESEARCH$824,461Yes
93.855ALLERGY AND INFECTIOUS DISEASES RESEARCH$757,190Yes
93.855ALLERGY AND INFECTIOUS DISEASES RESEARCH$556,571Yes
12.910RESEARCH AND TECHNOLOGY DEVELOPMENT$519,438Yes
93.855ALLERGY AND INFECTIOUS DISEASES RESEARCH$500,822Yes
93.RDEfficacy studies in SUDV (Gulu variant) challenged Rhesus macaque non-human primates (NHP)$482,352Yes
93.279DRUG USE AND ADDICTION RESEARCH PROGRAMS$441,845Yes
93.242MENTAL HEALTH RESEARCH GRANTS$435,479Yes
93.866AGING RESEARCH$430,004Yes
93.RDStrong Heart Study Cardiovascular Center$390,730Yes
93.855ALLERGY AND INFECTIOUS DISEASES RESEARCH$389,450Yes
93.859BIOMEDICAL RESEARCH AND RESEARCH TRAINING$374,920Yes
93.855ALLERGY AND INFECTIOUS DISEASES RESEARCH$371,821Yes
93.279DRUG USE AND ADDICTION RESEARCH PROGRAMS$354,745Yes
12.420MILITARY MEDICAL RESEARCH AND DEVELOPMENT$321,279Yes
93.RDEfficacy Testing of a Marburg Virus Monoclonal Antibody Medical Countermeasure$314,452Yes

What findings did the auditor report?

The reference is the auditor’s; the requirement is the Compliance Supplement category the auditor selected. The finding text itself is not reproduced here; the FAC report linked above carries it in full. What the two severity levels mean: material weakness vs significant deficiency.

Findings on the most recent report
ReferenceRequirementSeverityRepeat
2025-001Procurement and suspension and debarment (I)Material weakness / Questioned costsYes

Form 990 and IRS registration

Form 990 "accounting fees" (Part IX line 11c) cover all accounting services reported by the organization and are not the price of an audit engagement.

Where to find the return itself, and what our Form 990 data covers: Form 990 lookup.

Most recent return
990 for 2024-12
Total revenue
$75,183,345
Total assets
$366,564,882
Accounting fees (Part IX line 11c)
$162,506
Paid preparer
RSM US LLP
IRS object id
202523169349307837
NTEE code
H40
Exempt under
501(c)(3)
Ruling year
1953
BMF release
2026-10-20

Read next

How we computed this

Every row comes from the Federal Audit Clearinghouse record named beside it, one report per audit year, with a resubmission superseding the filing it replaces. The auditor is the one named on that filing — it is not a statement about who audits TEXAS BIOMEDICAL RESEARCH INSTITUTE now. Form 990 figures come from the IRS e-filed return named by its object id. This page exists because the organization filed at least two single audits, or one with a finding.

Cite this page

AuditRadar. “Texas Biomedical Research Institute Single Audits 2016–2025.” https://getauditradar.com/single-audits/tx/texas-biomedical-research-institute-741109630/. Data as of 2026-11-06.